Merger

Recorded: 2019-09-12 Pages: 6

Assignor

NLS PHARMA AG

Executed: 2019-07-17

Assignee

NLS-1 PHARMA AG

ALTER POSTPLATZ 2, STANS, 6370, SWITZERLAND

Covered Property (1)

Phacetoperane for Treating of Attention Deficit Hyperactivity Disorder

Patent: 10,456,387 →

Application: 15/913,481 →

Publication: US 2018/0214436

Related Assignments (1)

Other recorded transfers of the patent in this record — the chain of ownership.